Pfizer Announces Third Indication Approval of Cejemly® (Sugemalimab) in China for Relapsed or Refractory Extranodal NK/T-cell Lymphoma

Pfizer announced on October 30 that the third indication of its innovative oncology immunotherapy Zhejie Stone® (generic name: Sugemalimab Injection) has been granted conditional approval by the National Medical Products Administration (NMPA) of China for monotherapy to treat adult patients with relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL). This approval is based on the results of the GEMSTONE-201 study, which aimed to evaluate the efficacy and safety of Zhejie Stone as a monotherapy for adult patients with relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL). Zhejie Stone is the world's first PD-L1 antibody approved for treating relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL). Since the end of 2021, Zhejie Stone has been approved in China for two indications in the field of non-small cell lung cancer.